Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo Biloba Extract in Schizophrenia
NCT05258123Completed
- Sponsor
- Peking University Huilongguan Hospital
- Start
- May 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ginkgo biloba extract in schizophrenia (2 arms), sponsored by Peking University Huilongguan Hospital. Primary endpoints: Positive and Negative Syndrome Scale at 12 weeks and Repeatable Battery for the Assessment of Neuropsychological Status at 12 weeks. Started May 2017; status: completed.
02
Drugs
ginkgo biloba extract
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05258123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258123.